ERBB3 and head and neck squamous cell carcinoma: This trial compared cetuximab to a dual HER3 and EGFR targeting IgG1 antibody (duligotuzumab) in patients with recurrent or metastatic SCCHN who have progressed on at least one platinum-based regimen.